Literature DB >> 9169612

Characterization of the human multidrug resistance protein containing mutations in the ATP-binding cassette signature region.

E Bakos1, I Klein, E Welker, K Szabó, M Müller, B Sarkadi, A Váradi.   

Abstract

A number of mutants with single amino acid replacements were generated in the highly conserved ATP-binding cassette (ABC)-signature region (amino acids 531-543) of the N-terminal half of the human multidrug resistance (MDR1) protein. The cDNA variants were inserted into recombinant baculoviruses and the MDR1 proteins were expressed in Spodoptera frugiperda (Sf9) insect cells. The level of expression and membrane insertion of the MDR1 variants was examined by immunostaining, and MDR1 function was followed by measuring drug-stimulated ATPase activity. We found that two mutations, L531R and G534V, practically eliminated MDR1 expression; thus these amino acid replacements seem to inhibit the formation of a stable MDR1 protein structure. The MDR1 variants G534D and I541R were expressed at normal levels with normal membrane insertion, but showed a complete loss of drug-stimulated ATPase activity, while mutant R538M yielded full protein expression but with greatly decreased ATPase activity. Increasing the ATP concentration did not restore MDR1 ATPase activity in these variants. Some amino acid replacements in the ABC-signature region (K536I, K536R, I541T and R543S) affected neither the expression and membrane insertion nor the ATPase function of MDR1. We found no alteration in the drug-sensitivity of ATP cleavage in any of the MDR1 variants that had measurable ATPase activity. These observations suggest that the ABC-signature region is essential for MDR1 protein stability and function, but alterations in this region do not seem to modulate MDR1-drug interactions directly.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9169612      PMCID: PMC1218382          DOI: 10.1042/bj3230777

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  27 in total

1.  Identification of mutations in regions corresponding to the two putative nucleotide (ATP)-binding folds of the cystic fibrosis gene.

Authors:  B S Kerem; J Zielenski; D Markiewicz; D Bozon; E Gazit; J Yahav; D Kennedy; J R Riordan; F S Collins; J M Rommens
Journal:  Proc Natl Acad Sci U S A       Date:  1990-11       Impact factor: 11.205

2.  Functional role for the 170- to 180-kDa glycoprotein specific to drug-resistant tumor cells as revealed by monoclonal antibodies.

Authors:  H Hamada; T Tsuruo
Journal:  Proc Natl Acad Sci U S A       Date:  1986-10       Impact factor: 11.205

3.  Structural model of the nucleotide-binding conserved component of periplasmic permeases.

Authors:  C S Mimura; S R Holbrook; G F Ames
Journal:  Proc Natl Acad Sci U S A       Date:  1991-01-01       Impact factor: 11.205

4.  Structural model of ATP-binding proteins associated with cystic fibrosis, multidrug resistance and bacterial transport.

Authors:  S C Hyde; P Emsley; M J Hartshorn; M M Mimmack; U Gileadi; S R Pearce; M P Gallagher; D R Gill; R E Hubbard; C F Higgins
Journal:  Nature       Date:  1990-07-26       Impact factor: 49.962

5.  Discrete mutations introduced in the predicted nucleotide-binding sites of the mdr1 gene abolish its ability to confer multidrug resistance.

Authors:  M Azzaria; E Schurr; P Gros
Journal:  Mol Cell Biol       Date:  1989-12       Impact factor: 4.272

6.  Mutations within the first LSGGQ motif of Ste6p cause defects in a-factor transport and mating in Saccharomyces cerevisiae.

Authors:  B L Browne; V McClendon; D M Bedwell
Journal:  J Bacteriol       Date:  1996-03       Impact factor: 3.490

7.  A cluster of cystic fibrosis mutations in the first nucleotide-binding fold of the cystic fibrosis conductance regulator protein.

Authors:  G R Cutting; L M Kasch; B J Rosenstein; J Zielenski; L C Tsui; S E Antonarakis; H H Kazazian
Journal:  Nature       Date:  1990-07-26       Impact factor: 49.962

8.  Expression of the human multidrug transporter in insect cells by a recombinant baculovirus.

Authors:  U A Germann; M C Willingham; I Pastan; M M Gottesman
Journal:  Biochemistry       Date:  1990-03-06       Impact factor: 3.162

9.  Use of recombinant P-glycoprotein fragments to produce antibodies to the multidrug transporter.

Authors:  S Tanaka; S J Currier; E P Bruggemann; K Ueda; U A Germann; I Pastan; M M Gottesman
Journal:  Biochem Biophys Res Commun       Date:  1990-01-15       Impact factor: 3.575

10.  Distantly related sequences in the alpha- and beta-subunits of ATP synthase, myosin, kinases and other ATP-requiring enzymes and a common nucleotide binding fold.

Authors:  J E Walker; M Saraste; M J Runswick; N J Gay
Journal:  EMBO J       Date:  1982       Impact factor: 11.598

View more
  14 in total

1.  Lipopolysaccharide transport involves long-range coupling between cytoplasmic and periplasmic domains of the LptB2FGC extractor.

Authors:  Emily A Lundstedt; Brent W Simpson; Natividad Ruiz
Journal:  J Bacteriol       Date:  2020-12-23       Impact factor: 3.490

2.  CFTR channel opening by ATP-driven tight dimerization of its nucleotide-binding domains.

Authors:  Paola Vergani; Steve W Lockless; Angus C Nairn; David C Gadsby
Journal:  Nature       Date:  2005-02-24       Impact factor: 49.962

3.  The detergent-soluble maltose transporter is activated by maltose binding protein and verapamil.

Authors:  R Reich-Slotky; C Panagiotidis; M Reyes; H A Shuman
Journal:  J Bacteriol       Date:  2000-02       Impact factor: 3.490

4.  Role of glycine-534 and glycine-1179 of human multidrug resistance protein (MDR1) in drug-mediated control of ATP hydrolysis.

Authors:  G Szakács; C Ozvegy; E Bakos ; B Sarkadi; A Váradi
Journal:  Biochem J       Date:  2001-05-15       Impact factor: 3.857

5.  Mutations in the linker domain of NBD2 of SUR inhibit transduction but not nucleotide binding.

Authors:  Michinori Matsuo; Michael Dabrowski; Kazumitsu Ueda; Frances M Ashcroft
Journal:  EMBO J       Date:  2002-08-15       Impact factor: 11.598

6.  The human multidrug resistance protein 4 (MRP4, ABCC4): functional analysis of a highly polymorphic gene.

Authors:  Nada Abla; Leslie W Chinn; Tsutomu Nakamura; Li Liu; Conrad C Huang; Susan J Johns; Michiko Kawamoto; Doug Stryke; Travis R Taylor; Thomas E Ferrin; Kathleen M Giacomini; Deanna L Kroetz
Journal:  J Pharmacol Exp Ther       Date:  2008-03-25       Impact factor: 4.030

7.  Effect of cysteine mutagenesis on the function and disulfide bond formation of human ABCG2.

Authors:  Yang Liu; Youyun Yang; Jing Qi; Hui Peng; Jian-Ting Zhang
Journal:  J Pharmacol Exp Ther       Date:  2008-04-22       Impact factor: 4.030

Review 8.  Efflux-mediated antifungal drug resistance.

Authors:  Richard D Cannon; Erwin Lamping; Ann R Holmes; Kyoko Niimi; Philippe V Baret; Mikhail V Keniya; Koichi Tanabe; Masakazu Niimi; Andre Goffeau; Brian C Monk
Journal:  Clin Microbiol Rev       Date:  2009-04       Impact factor: 26.132

9.  The linker region of breast cancer resistance protein ABCG2 is critical for coupling of ATP-dependent drug transport.

Authors:  S Macalou; R W Robey; G Jabor Gozzi; S Shukla; I Grosjean; T Hegedus; S V Ambudkar; S E Bates; A Di Pietro
Journal:  Cell Mol Life Sci       Date:  2015-12-26       Impact factor: 9.261

10.  Single-nucleotide polymorphisms in a short basic motif in the ABC transporter ABCG2 disable its trafficking out of endoplasmic reticulum and reduce cell resistance to anticancer drugs.

Authors:  Wenji Zhang; Yang Yang; Zizheng Dong; Zhi Shi; Jian-Ting Zhang
Journal:  J Biol Chem       Date:  2019-11-12       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.